MOREPEN LABS – Future Multibagger upto 5x Potential upmove

Cmp – 39

Market Cap – 1750cr

Face value- Rs.2

Book Value – 6.75

52wk High/Low – 41.75/13.80

5 years High/Low – 44.45( jan 2018)/7.20( March’20)

ROE – 12.50% ( Atmost at 10 year High)

ROCE – 10.25% ( Increasing Cont from last few years)

Best To Accmulate – 32 To 36 zone

TECHNICALLY- Once it closes above 45.55 & Suatains can see clean upmove

Test Levels # 75 ( 12 to 18 months)/ 110 ( 18 To 30 Months)/ 200+ ( 36 To 48 Months)

S/L – As per Risk or 25.95 on closing basis

Management About Growth – Very Optimistic about Next 5 to 7 years ( From 4 billion To 40 billion dollar company)

🔅Morepen Lab is three-and-a-half decade old company, It has always aspired to be an organisation with tangible, visible differences where every individual action is inspired by a deep, humbling desire to make a difference to the lives we touch. Its state-of-art manufacturing facility in the picturesque environs of Baddi comprises a scientifically integrated complex of 10 plants, each with a specific product profile. The company’s extensive R&D facilities and factories are manned by a dedicated team of professionals who ensure stringent quality standards. With a strong global presence, Morepen exports to over 75 countries with certifications from all major regulatory authorities like USFDA, WHO GMP, EU GMP. Our domestic products under the brand name, Dr. Morepen and Gubb world have a huge range of healthcare, grooming and OTC products trusted by over 100 million consumers.

A global leader in Bulk Drug APIs production with USFDA approved facilities.

Govt. of India recognized R&D Centre with focus on anti-diabetic, anti-depressants and anti-coagulant.

Over 25 new molecules in advance stage of development with non-infringing process, excellent impurity profile and complete documentation.

Largest producer of Montelukast in the world with 60 MT capacity per annum

Over 90% market share of Generic Loratadine in US Market with 150MT capacity per annum.
The top lead player manufacturer of block buster drug, Atorvastatin with
market size of US$18 bn
Morepen’s Lab R&D team to innovate non-infringing technologies and cost-effective processes in order to achieve world-class quality and high yields for the generic market. Its R&D team’s consistent ability to create new polymorphs of complex new molecules not only gives Morepen its unique strategic edge but also enables the company to break fresh grounds and capture new markets locally & globally on the strength of innovation.

🔅25+ New molecules in Advance stage of Development

🔅WHO,USFDA Approved Quality controlled process.

🔅54+ patents awarded Globally and Regionally.

🔅45+ Drug master Files published for all API’s with international standard

Specialized Chemical Synthesis

  • Acetylation/ Alkylation Reaction
  • Amine/ Hydroxy Deprotection
  • Amino Acid Coupling
  • Ester Hydrolysis
  • Chiral Synthesis
  • Condensation Reaction
  • Cyanation Reaction
  • Grignard Reaction
  • Friedel Craft Reaction
  • Hetero Cyclization
  • High pressure Hydrogenation
  • α, β-Enzymatic Oxidation
  • Reduction  Reaction
  • Esterification
  • Nucleophilic Substitution
  • Oxidation Reaction

Disclaimer – All views expressed are personal and only for educational and study purpose. Consult your financial advisor before investing or taking any position based on above article.

2 thoughts on “MOREPEN LABS – Future Multibagger upto 5x Potential upmove

  1. Can you update Regarding IT stock dollar is on top and IT stock down near 52 week low
    When it will be start upward journey.
    Can pl. Update can it again top in Jan-23
    Because every year in Jan. all IT stock at top or new heigh
    Pl. Update in telegram site
    Nimesh Patel

    Liked by 1 person

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s